Detalles de la búsqueda
1.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Cancer
; 129(7): 992-1004, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36692409
2.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31860137
3.
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Hematol Oncol
; 38(3): 372-380, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32271957
4.
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax.
Am J Hematol
; 98(4): E80-E83, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36651870
5.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Am J Hematol
; 98(8): E204-E208, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37222267
6.
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC".
Cancer Med
; 12(3): 3180-3184, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208021
7.
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
Leuk Res
; 114: 106803, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35150967
8.
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.
Blood Cancer J
; 14(1): 53, 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38531834
9.
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
Leuk Res
; 74: 75-79, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30308414
10.
Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
Leuk Res
; 115: 106811, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219543
Resultados
1 -
10
de 10
1
Próxima >
>>